In vitro activity of isavuconazole against 1488 Aspergillus isolates a pooled analysis of nine studies

J. Smart*, M. Jones, N. Azie

Author address: 

(Deerfield, US; Basel, CH)

Abstract: 

Background: Invasive aspergillosis remains an important cause of morbidity and mortality. Isavuconazole (ISA) is a novel, intravenous and orally available, broad-spectrum, water-soluble triazole currently in Phase III clinical trials for treatment of patients with invasive Aspergillus, Candida, and rare mould infections, including patients with renal impairment. The active moiety of ISA is BAL4815, which has been shown to have in vitro antifungal activity against clinically relevant species of yeasts and moulds including Aspergillus as well as Zygomycetes. Methods and Results: We examined the in vitro activity of ISA against 1488 isolates of Aspergillus (Table 1). These data represent a compilation of minimal inhibitory concentration (MIC) data from 7 published reports and 2 unpublished laboratory studies undertaken by various academic investigators in EU and US laboratories during the period 20042010. All MIC data in the pooled analysis were derived using CLSI (M38-A) or EUCAST standard methodologies, although there were differences in methodologies between the test centers related to incubation period, determination of MIC endpoint, and number of replicates. Results: Overall, ISA was active against all clinically relevant species of Aspergillus tested. The MIC results were evaluated at either 24 hours or 48 hours. The ISA and voriconazole (VRC) MIC ranges, MIC50s, and MIC90s are listed in Table 1 for each of the Aspergillus species tested. For the majority of the Aspergillus species, the 24 and 48 hour
2012

abstract No: 

P816

Full conference title: 

22nd European Congress of Clinical Microbiology and Infectious Diseases
    • ECCMID 22nd (2012)